# NTRK2

## Overview
The NTRK2 gene encodes the neurotrophic receptor tyrosine kinase 2 (TrkB), a receptor tyrosine kinase that plays a pivotal role in the nervous system's development and function. TrkB is primarily activated by neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), which initiate signaling pathways crucial for neuronal survival, differentiation, and synaptic plasticity (Nakagawara1995Cloning; Gray2006Functional). Structurally, TrkB is a transmembrane protein comprising extracellular, transmembrane, and intracellular domains, with the latter containing a tyrosine kinase domain essential for its activity (Nakagawara1995Cloning). The receptor's activation involves dimerization and phosphorylation, facilitating interactions with adaptor proteins that trigger downstream signaling cascades (Gray2006Functional). TrkB is expressed in various central nervous system regions, influencing processes such as learning and memory, and its dysregulation is linked to conditions like obesity and developmental delays (Gray2006Functional). The clinical significance of NTRK2 extends to oncology, where gene fusions involving NTRK2 are implicated in several cancers, making it a target for therapeutic interventions (Torre2020Molecular; Joshi2019Revisiting).

## Structure
The NTRK2 gene encodes the TRK-B protein, a receptor tyrosine kinase involved in neurotrophin signaling. The full-length TRK-B protein is composed of three major domains: a 1290-bp extracellular domain (430 amino acids), a 72-bp transmembrane domain (24 amino acids), and a 1104-bp intracellular domain (368 amino acids) (Nakagawara1995Cloning). The extracellular domain contains 13 cysteine residues and 12 potential N-glycosylation sites, which are important for protein stability and function (Nakagawara1995Cloning). The intracellular domain includes a characteristic tyrosine kinase domain with a putative ATP-binding site sequence, essential for its kinase activity (Nakagawara1995Cloning).

The TRK-B protein undergoes post-translational modifications, including phosphorylation, which is crucial for its activation and signaling (Weiss2021NTRK). The protein can form dimers upon ligand binding, which is part of its quaternary structure and necessary for its function (Yang2024Critical). Splice variants of TRK-B result in different isoforms, including a truncated form that lacks part of the intracellular domain, affecting its signaling capabilities (Nakagawara1995Cloning). These structural features enable TRK-B to play a significant role in the development and maintenance of the nervous system.

## Function
The NTRK2 gene encodes the TrkB receptor, a receptor tyrosine kinase that plays a crucial role in the development and function of the nervous system. TrkB is primarily activated by binding to neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), which triggers a cascade of intracellular signaling pathways essential for neuronal survival, differentiation, and synaptic plasticity (Nakagawara1995Cloning; Gray2006Functional).

Upon activation, TrkB undergoes homodimerization and transphosphorylation, leading to the phosphorylation of several tyrosine residues. These phosphorylated residues serve as docking sites for adaptor proteins like Shc and phospholipase C-gamma (PLC-g), which activate downstream signaling pathways, including the mitogen-activated protein kinase (MAPK) and Akt pathways. These pathways are critical for promoting neurite outgrowth, cell proliferation, and survival (Gray2006Functional).

TrkB is expressed in various regions of the central nervous system, including the cerebral cortex, hippocampus, thalamus, and spinal cord, where it influences processes such as learning and memory (Nakagawara1995Cloning). The receptor's activity is essential for maintaining neuronal plasticity and energy homeostasis, with mutations in NTRK2 linked to severe obesity and developmental delays (Gray2006Functional).

## Clinical Significance
Mutations and alterations in the NTRK2 gene, which encodes the TRKB receptor, have been implicated in various diseases and conditions. In the context of cancer, NTRK2 fusions have been identified as oncogenic drivers in several malignancies, including gliomas and acute myeloid leukemia (AML). These fusions can lead to constitutive activation of TRK signaling pathways, promoting tumor growth and survival. Targeted therapies, such as TRK inhibitors larotrectinib and entrectinib, have shown efficacy in treating cancers with NTRK2 fusions, although resistance can develop due to co-occurring mutations (Torre2020Molecular; Joshi2019Revisiting; Cocco2018NTRK).

Beyond oncology, NTRK2 mutations are associated with neurological and psychiatric disorders. Alterations in NTRK2 expression or function can lead to obesity, mood disorders, and cognitive impairments. The BDNF-TRKB axis, involving NTRK2, is crucial for neuronal development and function, and its disruption can result in hyperphagia, obesity, and defects in memory and learning (Chetty2019Neurotrophic; Cocco2018NTRK). These findings underscore the clinical significance of NTRK2 in both cancer and neurological conditions, highlighting its potential as a therapeutic target.

## Interactions
The NTRK2 gene encodes the TrkB protein, which is involved in various protein interactions critical for its signaling functions. TrkB interacts with adaptor proteins such as Shc and PLCγ, which are essential for activating downstream signaling pathways like Ras/ERK and PI3K-Akt (Gupta2024Atypical). The phosphorylation of specific tyrosine residues within TrkB is crucial for these interactions, facilitating the recruitment of signaling molecules (Gupta2024Atypical).

TrkB also interacts with the EGF receptor (EGFR), where EGF-induced transactivation of TrkB promotes cell migration, although this effect differs from the atypical TrkB signaling observed in some studies (Gupta2024Atypical). The TrkB.T1 isoform, a kinase-deficient variant, acts as a dominant-negative regulator by sequestering BDNF, limiting its availability for full-length TrkB activation, and impairing BDNF signaling (Tessarollo2022TrkB).

In gliomas, TrkB.T1 enhances oncogenic signaling pathways, including PI3K/Akt, by interacting with other receptor tyrosine kinases and affecting endocytic trafficking (Pattwell2020A). The NACC2-NTRK2 fusion protein involves interactions mediated by the BTB domain, which is crucial for multimerization and activation of downstream signaling pathways such as MAPK, PLCγ1, and STAT3 (Yang2024Critical). These interactions highlight the diverse roles of NTRK2 in cellular signaling and cancer biology.


## References


[1. (Torre2020Molecular) Matthew Torre, Varshini Vasudevaraja, Jonathan Serrano, Michael DeLorenzo, Seth Malinowski, Anne-Florence Blandin, Melanie Pages, Azra H. Ligon, Fei Dong, David M. Meredith, MacLean P. Nasrallah, Craig Horbinski, Sonika Dahiya, Keith L. Ligon, Mariarita Santi, Shakti H. Ramkissoon, Mariella G. Filbin, Matija Snuderl, and Sanda Alexandrescu. Molecular and clinicopathologic features of gliomas harboring ntrk fusions. Acta Neuropathologica Communications, July 2020. URL: http://dx.doi.org/10.1186/s40478-020-00980-z, doi:10.1186/s40478-020-00980-z. This article has 89 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40478-020-00980-z)

[2. (Joshi2019Revisiting) Sunil K. Joshi, Monika A. Davare, Brian J. Druker, and Cristina E. Tognon. Revisiting ntrks as an emerging oncogene in hematological malignancies. Leukemia, 33(11):2563–2574, September 2019. URL: http://dx.doi.org/10.1038/s41375-019-0576-8, doi:10.1038/s41375-019-0576-8. This article has 32 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41375-019-0576-8)

[3. (Gray2006Functional) J Gray, G Yeo, C Hung, J Keogh, P Clayton, K Banerjee, A McAulay, S O’Rahilly, and I S Farooqi. Functional characterization of human ntrk2 mutations identified in patients with severe early-onset obesity. International Journal of Obesity, 31(2):359–364, May 2006. URL: http://dx.doi.org/10.1038/sj.ijo.0803390, doi:10.1038/sj.ijo.0803390. This article has 89 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/sj.ijo.0803390)

[4. (Yang2024Critical) Wei Yang, April N. Meyer, Zian Jiang, Xuan Jiang, and Daniel J. Donoghue. Critical domains for nacc2-ntrk2 fusion protein activation. PLOS ONE, 19(6):e0301730, June 2024. URL: http://dx.doi.org/10.1371/journal.pone.0301730, doi:10.1371/journal.pone.0301730. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0301730)

[5. (Cocco2018NTRK) Emiliano Cocco, Maurizio Scaltriti, and Alexander Drilon. Ntrk fusion-positive cancers and trk inhibitor therapy. Nature Reviews Clinical Oncology, 15(12):731–747, October 2018. URL: http://dx.doi.org/10.1038/s41571-018-0113-0, doi:10.1038/s41571-018-0113-0. This article has 1005 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41571-018-0113-0)

[6. (Tessarollo2022TrkB) Lino Tessarollo and Sudhirkumar Yanpallewar. Trkb truncated isoform receptors as transducers and determinants of bdnf functions. Frontiers in Neuroscience, March 2022. URL: http://dx.doi.org/10.3389/fnins.2022.847572, doi:10.3389/fnins.2022.847572. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2022.847572)

[7. (Chetty2019Neurotrophic) Runjan Chetty. Neurotrophic tropomyosin or t﻿yrosine receptor kinase (ntrk) genes. Journal of Clinical Pathology, 72(3):187–190, January 2019. URL: http://dx.doi.org/10.1136/jclinpath-2018-205672, doi:10.1136/jclinpath-2018-205672. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1136/jclinpath-2018-205672)

[8. (Weiss2021NTRK) Lawrence M. Weiss and Vincent A. Funari. Ntrk fusions and trk proteins: what are they and how to test for them. Human Pathology, 112:59–69, June 2021. URL: http://dx.doi.org/10.1016/j.humpath.2021.03.007, doi:10.1016/j.humpath.2021.03.007. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.humpath.2021.03.007)

[9. (Pattwell2020A) Siobhan S. Pattwell, Sonali Arora, Patrick J. Cimino, Tatsuya Ozawa, Frank Szulzewsky, Pia Hoellerbauer, Tobias Bonifert, Benjamin G. Hoffstrom, Norman E. Boiani, Hamid Bolouri, Colin E. Correnti, Barbara Oldrini, John R. Silber, Massimo Squatrito, Patrick J. Paddison, and Eric C. Holland. A kinase-deficient ntrk2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways. Nature Communications, June 2020. URL: http://dx.doi.org/10.1038/s41467-020-16786-5, doi:10.1038/s41467-020-16786-5. This article has 28 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-16786-5)

[10. (Gupta2024Atypical) Rohini Gupta, Melanie Dittmeier, Gisela Wohlleben, Vera Nickl, Thorsten Bischler, Vanessa Luzak, Vanessa Wegat, Dennis Doll, Annemarie Sodmann, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Jahnve Gupta, Evi Horn, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Jörg Wischhusen, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Atypical cellular responses mediated by intracellular constitutive active trkb (ntrk2) kinase domains and a solely intracellular ntrk2-fusion oncogene. Cancer Gene Therapy, July 2024. URL: http://dx.doi.org/10.1038/s41417-024-00809-0, doi:10.1038/s41417-024-00809-0. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41417-024-00809-0)

[11. (Nakagawara1995Cloning) Akira Nakagawara, Xing-Ge Liu, Naohiko Ikegaki, Peter S. White, Darrell J. Yamashiro, Lynn M. Nycum, Jaclyn A. Biegel, and Garrett M. Brodeur. Cloning and chromosomal localization of the human trk-b tyrosine kinase receptor gene (ntrk2). Genomics, 25(2):538–546, January 1995. URL: http://dx.doi.org/10.1016/0888-7543(95)80055-q, doi:10.1016/0888-7543(95)80055-q. This article has 77 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0888-7543(95)80055-q)